Metallothioneins are ubiquitous low molecular weight proteins characterised by high cysteine content, paucity of aromatic amino acids and selective binding of heavy metals such as zinc, copper and cadmium. They are present in all vertebrates studied and are grouped into two classes, MT I and MT II, solely on the basis of their chromatographic behaviour. Their synthesis has been shown to be induced by several agents, most consistently by metals but also, importantly, by stress conditions such as starvation, cold and strenuous exercise, this being related to hormonal control at the cellular level by glucocorticoids and interferon, regulation ocurring at the level of transcription initiation. (For review see Hamer, 1986) .
Since their discovery (Margoshes and Vallee, 1957) and characterisation (Kagi and Vallee, 1960 ) the function of metallothioneins has been debated. There is evidence for a role in detoxification and they are also believed to be involved in copper and zinc metabolism (Webbs and Cain 1982) . However, cell lines which fail to synthesise metallothionein are fully viable with a normal cell doubling time (Comper and Palmiter, 1981) , arguing against an essential role for the intracellular activation of metalloenzymes involved in cell division.
Recently, metallothionein has been found to be elevated in neoplastic cells (Murphy et al., 1991) and overexpression has been found to confer resistance to radiotherapy (Thornally and Vasak 1985; Renan and Dowman, 1989) and chemotherapeutic agent toxicity (Andrews et al.,1987; Kelley et al., 1988; Webber et al., 1988; Kaina et al., 1990) , although this has been disputed (Schilder et al., 1990; Murphy et al., 1991) . Metallothionein overexpression has been described in human breast carcinoma and appears to be associated with a poorer prognosis (Fresno et al., 1993; Schmid et al., 1993 (Page and Anderson, 1987; Ellis et al., 1992) Sections 3 ,um thick were also cut and used for immunohistochemical staining of metallothionein according to a standard ABC method. Briefly, the sections were dewaxed in xylene and taken to alcohol. Endogenous peroxidase activity was blocked with 0.5% hydrogen peroxide in methanol and the sections washed well in running tap water and rinsed in Tris-buffered saline (TBS). Non-specific binding sites were blocked by applying one-fifth normal swine serum in TBS (NSS/TBS) and excess NSS drained before applying the primary antibody, MT E9, used in its unfractionated ascites fluid preparation form (Jasani and Elmes, 1991; Schmid et al., 1993) at a dilution of 1:10 000 in NSS/TBS for 30-60 min. After washing in TBS, biotinylated secondary antibody was applied, the sections washed again and preformed avidin-biotin complex applied. After further washing, the label was developed using DAB solution and the sections subsequently counterstained in haematoxylin. Analysis of relationships to other variables was tested by the chi-square test with Yates' correction. Disease-free interval and survival curves were calculated by Gehan's generalised Wilcoxon test using the SPSSX statistical computer package (SSPS, 1986) . In accordance with convention a Pvalue of< 0.05 was accepted as significant.
Results
Many of the tissue sections used contained normal breast tissue in addition to the carcinoma and we were able to confirm previous observations by other authors of consistently positive metallothionein expression in myoepithelial cells, expression in only occasional ductal epithelial cells and the absence of expression in epithelial cells within the lobules (Schmid et al., 1993; Bier et al., 1994) as indicated in Figure  1 . In general, the staining was easy to interpret and metallothionein could be demonstrated in the cytoplasm, nucleus or both in normal and malignant cells. Although several tumour sections also contained areas of in situ carcinoma, only the invasive component was assessed for metallothionein expression. An example of a tumour showing high levels of expression is shown in Figure 2 . One patient was lost to follow-up and therefore excluded. The remaining 99 cases showed considerable variation in the degree of metallothionein expression in the tumour cells (Table II) . Statistical analysis revealed a significant association between metallothionein expression and the groups of tumour type (P<0.001), with low levels of expression being observed in tumours of good prognostic subtypes (Table IV) . There was also a significant association between high levels of expression and local recurrence (P<0.02, Table V in patients whose tumours showed a high level of metallothionein expression (Figures 3 and 4 (Figures 5 and 6 ).
There was no significant association between metallothionein expression and the other tumour and patient variables examined (probability values for chi-square test given in Table III ). Chi-square, 9.57370, d.f., 3, P<0.02.
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Discussion
We chose to examine the expression of metallothionein in human breast carcinoma using an immunohistochemical technique as this has the major advantage over other methods -either indirect (e.g. chromatographic separation) or direct (e.g. radioimmunoassay) -of allowing localisation of metallothionein within the tissue examined. Furthermore, the technique, which is now well established, is possible with routinely fixed and processed tissue, without the need for preselection of tissue for separate analysis. This study confirms metallothionein overexpression in invasive breast carcinoma and further, our finding of no significant association between metallothionein and tumour size suggests that where overexpression does occur it does so early in the lifetime of the tumour, possibly during carcinogenesis. This would be consistent with previous reports of metallothionein induction occuring during carcinogenesis (Angel et al., 1986) and ultraviolet irradiation and a recent observation of increased metallothionein expression in breast epithelial hyperplasias and ductal carcinoma in situ (Bier et al., 1994) , but does not necessarily imply a causative role. With their affinity to bind potentially carcinogenic metals (e.g. cadmium) (Hamer, 1986) and metabolites (e.g. free radicals) (Thornally and Vasak, 1985) metallothioneins do have the potential to effect the carcinogenic process in a way which may be either deleterious or protective to the cell. Whatever the involvement of metallothionein may be in carcinogenesis and tumour progression, in our study, with a minimum of 12 years follow-up, we have confirmed an association between increased expression and poor prognosis as has been described previously in studies with shorter follow-up times (Fresno et al., 1993; Schmid et al., 1993) .
We have confirmed the variation of expression of metallothionein in both normal and neoplastic breast tissues (Fresno et al., 1993; Schmid et al., 1993; Bier et al., 1994) with tumours of favourable prognostic subtype showing significantly lower levels of expression than tumours of poor prognostic subtype. Our preliminary study and those of others (Fresno et al., 1993; Schmid et al., 1993; Bier et al., 1994) have shown lack of expression in normal lobular epithelium and little or no expression in lobular carcinomas. While we do not wish to suggest that the lack of expression in both benign lobular epithelium and lobular carcinoma implies that lobular carcinoma arises from lobular epithelium, we note the observation with interest. Differences in metallothionein expression between different tumour types is another manifestation of their phenotypic diversity and may, at least in part, explain the observed differences in prognosis. Further studies with larger numbers of specimens are required to assess the significance of metallothionein overexpression in different tumour types.
We looked specifically for an association between metallothionein expression and tumour grade but, unlike Fresno et al. (1993) , we found the level of metallothionein expression to be independent of the degree of differentiation of the tumour. Thus, although the good prognostic tumour types may be expected often to be of lower grade than the poor prognostic types, this alone cannot account for our observation of an association between tumour type and metallothionein expression.
We found no association between metallothionein expression and ER status, although such an association has been described (Fresno et al., 1993) and it has been further suggested that metallothionein overexpression is associated with a poor prognosis only in ER-negative tumours, the association being lost in ER-positive tumours which would be expected to respond to anti-oestrogen therapy (Schmid et al., 1993) . This may be of particular significance if metallothionein overexpression is associated with resistance to chemotherapy and radiotherapy in breast carcinoma as has been suggested for other tumours (Andrews et al., 1987; Kelley et al., 1988; Renan and Dowman, 1989) , as it is those patients with ER-negative tumours who are likely to be assigned to such a therapeutic regimen rather than anti-oestrogen therapy.
Although much remains uncertain regarding the physiological functions of metallothioneins and their role in carcinogenesis and other disease processes, and although immunohistochemical detection does not necessarily imply functional capability, we have found that elevated levels of expression detected in this way are associated with poor prognostic tumour types and with an increased likelihood of local recurrence, shortened disease-free interval and reduced survival. This may have implications for understanding the cellular origins, development and progression of human breast cancer.
